Près de 900.000 people live with Alzheimer’s disease in France, where approximately 225,000 new cases are diagnosed each year, according to figures highlighted by the Fondation pour la Recherche Médicale. As medical teams work to improve early detection and therapeutic interventions, clinical researchers are evaluating faster diagnostic tools and novel disease-modifying therapies that could reshape patient care across the country.
Blood Test Trials Target Faster Alzheimer’s Diagnosis in France
Diagnosing Alzheimer’s disease traditionally involves a lengthy and complex evaluation process. To address these delays, the University Hospital Center (CHU) of Nantes launched a clinical evaluation examining a simplified diagnostic blood test, according to Vincent Valinducq during an appearance on TF1’s “Bonjour ! La Matinale TF1.” The method detects a specific protein associated with the pathology directly from a standard blood sample.
Medical guidelines for the trial restrict the screening method to specific demographics. The blood test targets adults over the age of 55 who are already exhibiting cognitive symptoms, rather than functioning as a general screening tool for asymptomatic populations.
Therapeutic Developments and International Treatment Comparisons
Beyond diagnostics, clinical researchers are monitoring emerging pharmaceutical treatments designed to target underlying brain lesions associated with the condition. Two primary disease-modifying drugs are currently authorized and administered in the United States, the United Kingdom, and Italy, according to clinical reporting discussed on TF1. Early clinical trials indicate these medications can reduce cognitive decline by approximately 27% over an 18-month period.
Despite their availability abroad, these therapies have not yet received clearance for distribution in France. Regulatory reviews in the country continue to weigh the observed cognitive benefits against significant adverse side effects associated with the medications.
National Research Campaign and Public Funding
To support ongoing scientific investigations into neurodegenerative disorders, the Fondation pour la Recherche Médicale initiated its ninth national mobilization campaign. The fundraising drive seeks public contributions to advance laboratory studies and clinical trials aimed at identifying reliable preventative measures and curative therapies for Alzheimer’s disease.
Worth a look